These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


1361 related items for PubMed ID: 35477226

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Investigation of Plasmid Mediated mcr Colistin Resistance Gene in Clinical Enterobacterales Isolates].
    Özkaya E, Buruk CK, Tosun İ, Toraman B, Kaklıkkaya N, Aydın F.
    Mikrobiyol Bul; 2020 Apr; 54(2):191-202. PubMed ID: 32723275
    [Abstract] [Full Text] [Related]

  • 5. Reversal of carbapenemase-producing Klebsiella pneumoniae epidemiology from blaKPC- to blaVIM-harbouring isolates in a Greek ICU after introduction of ceftazidime/avibactam.
    Papadimitriou-Olivgeris M, Bartzavali C, Lambropoulou A, Solomou A, Tsiata E, Anastassiou ED, Fligou F, Marangos M, Spiliopoulou I, Christofidou M.
    J Antimicrob Chemother; 2019 Jul 01; 74(7):2051-2054. PubMed ID: 31002313
    [Abstract] [Full Text] [Related]

  • 6. [Evaluation of In Vitro Efficacy of Ceftazidime-Avibactam, Meropenem, and Colistin Single and Binary Combinations Against Carbapenem Resistant Klebsiella pneumoniae Strains Isolated from Various Clinical Specimens].
    Köle M, Sesli Çetin E, Şirin MC, Cicioğlu Arıdoğan B.
    Mikrobiyol Bul; 2022 Apr 01; 56(2):230-250. PubMed ID: 35477227
    [Abstract] [Full Text] [Related]

  • 7. In vitro Activity of Cefiderocol and Ceftazidime-Avibactam, Against Carbapenemase-Producing Enterobacterales.
    Ozyurt OK, Tufanoglu P, Cetinkaya O, Ozhak B, Yazisiz H, Ongut G, Turhan O, Ogunc D.
    Clin Lab; 2023 Jan 01; 69(1):. PubMed ID: 36649528
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. In vitro activity of ceftazidime-avibactam and comparators against OXA-48-like Enterobacterales collected between 2016 and 2020.
    Stone G, Wise M, Utt E.
    Microbiol Spectr; 2024 Mar 05; 12(3):e0147323. PubMed ID: 38329363
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Molecular epidemiology of carbapenem-resistant gram-negative bacilli in Ecuador.
    Soria-Segarra C, Soria-Segarra C, Molina-Matute M, Agreda-Orellana I, Núñez-Quezada T, Cevallos-Apolo K, Miranda-Ayala M, Salazar-Tamayo G, Galarza-Herrera M, Vega-Hall V, Villacis JE, Gutiérrez-Fernández J.
    BMC Infect Dis; 2024 Apr 06; 24(1):378. PubMed ID: 38582858
    [Abstract] [Full Text] [Related]

  • 17. Epidemiology and in vitro activity of ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, eravacycline, plazomicin, and comparators against Greek carbapenemase-producing Klebsiella pneumoniae isolates.
    Maraki S, Mavromanolaki VE, Magkafouraki E, Moraitis P, Stafylaki D, Kasimati A, Scoulica E.
    Infection; 2022 Apr 06; 50(2):467-474. PubMed ID: 34854060
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The Potential Use of Ceftazidime-Avibactam Against Carbapenem Resistant Klebsiella pneumoniae Clinical Isolates Harboring Different Carbapenemase Types in a Thai University Hospital.
    Nasomsong W, Nulsopapon P, Changpradub D, Pongchaidecha M, Pungcharoenkijkul S, Juntanawiwat P, Simsiriporn W, Santimaleeworagun W.
    Drug Des Devel Ther; 2021 Apr 06; 15():3095-3104. PubMed ID: 34295150
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 69.